#United States #gene therapy #Aurora #RheumaGen #Celiac Disease

RheumaGen Secures Funding to Tackle Celiac Disease

RheumaGen, Inc., a biotechnology company specializing in cell and gene therapy, has garnered attention following their recent announcement regarding a new funding agreement with Beyond Celiac Investments (BCI). This collaboration signifies a pivotal move toward developing groundbreaking treatments aimed at celiac disease. The funding was established through a Series A-1 preferred stock investment, designed to propel RheumaGen's celiac disease program through early development phases, ultimately striving to demonstrate preclinical proof of concept.

Dr. Jordan Dubow, Chief Medical Officer at Beyond Celiac, expressed enthusiasm regarding RheumaGen's advancements in rheumatoid arthritis treatment and their prospects in celiac disease therapy, stating, "BCI has a meticulous selection process, and RheumaGen exemplifies the type of innovative company we are eager to invest in." This investment highlights BCI's broader initiative to identify and fund early-stage candidates that have the potential for transformative impacts on celiac disease.

RheumaGen's unique approach involves utilizing an advanced HLA gene-editing platform, which aims to directly modify the immune response associated with autoimmune diseases. Richard Freed, CEO and Co-Founder of RheumaGen, conveyed gratitude for BCI's confidence in their pioneering drug development strategies. Freed noted, "Our innovative platform seeks to address the root cause of autoimmune disorders, providing a new avenue of hope for millions suffering from celiac disease who have long awaited a definitive cure."

Established through BCI's Catalyst Program, this investment reflects their commitment to support initiatives that show promise in progressing to clinical trials and delivering effective treatments. The funding also aligns with BCI's strategic mission to enhance patient care and ultimately bring forth the first available cures for celiac disease.

RheumaGen, headquartered in Aurora, Colorado, is at the forefront of developing a new class of therapeutics aimed at combating a variety of autoimmune diseases. By focusing on the human leukocyte antigen (HLA), often referred to as the "immune gene," the company distinguishes itself in the biotechnology field through its innovative, one-time gene therapy solutions. Additionally, RheumaGen collaborates with the ClinImmune Center for Clinical Immunology at the University of Colorado Anschutz Medical Campus to facilitate comprehensive clinical development and production.

As part of BCI's first-year fundraising endeavors, they exceeded initial expectations, paving the way for further investments into companies like RheumaGen that are working diligently to innovate within the medical field. BCI’s goal is not just limited to investments; it encompasses a vision to uplift the standard of care for celiac patients and advance the timeline toward viable treatments and curative options.

In conclusion, the partnership between RheumaGen and Beyond Celiac Investments marks an important milestone in the fight against celiac disease. As both entities move forward with heightened determination, the potential impact on patient wellbeing could be profound, rekindling hope for an effective cure for a condition that has afflicted many for far too long.